OakChart

MaxCyte Inc

MXCTHealthcare·Medical Devices·USA·Micro·NASD·Nov 12 • 7:51 AM ET

1.100.00 (0.00%)
2026-11-12 15:05 CET
Market cap
113.53 USD m
Revenue, TTM
34.37 USD m
Net income, TTM
-27.98 USD m
Free cash flow, TTM
-21.45 USD m
EPS diluted, TTM
-0.26
P/E
-
Compare

Price

MXCT against its 20, 50 and 200-day averages
2050200beat
Patternshover a marker to name it
Sales mean, own scalesmoothed
RS 11Sales 7.59Price7.517.780.751.001.251.501.757.0M14.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MXCTclose 1.1020-day 1.4050-day 1.25200-day 1.071.1052w high

39.1% under the 52-week high of 1.81 on 19 Nov 2025. 52-week low 0.64 on 17 Feb 2026. Last 15 sessions, 63.0% high to low

Volume 0.02× normal · the line is the 50-bar volume average

Profile

MXCT
52-week range, 40% of the way up
0.641.80

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

Employees91
IPODec 05, 2019
Beta1.49
ATR, 14d0.13
Rel volume0.02
Short float1.67%
Insider own8.12%
Inst own64.37%

Snapshot

6 groups

Valuation

Index-
Market Cap113.58M
Enterprise Value29.19M
Income-27.98M
Sales34.37M
Book/sh1.46
Cash/sh0.98
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees91
IPODec 05, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S3.30
P/B0.75
P/C1.12
P/FCF-
EV/EBITDA-
EV/Sales0.85
Quick Ratio7.37
Current Ratio7.83
Debt/Eq0.11
LT Debt/Eq0.10
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.26
EPS next Y-0.23
EPS next Q-0.07
EPS this Y39.11%
EPS next Y10.54%
EPS next 5Y22.67%
EPS past 3/5Y-21.85% -19.78%
Sales past 3/5Y-9.30% 4.76%
EPS Y/Y TTM38.72%
Sales Y/Y TTM-0.13%
EPS Q/Q60.52%
Sales Q/Q48.66%
EarningsNov 10 BMO
EPS/Sales Surpr.35.48% 37.35%

Ownership

Insider Own8.12%
Insider Trans0.00%
Inst Own64.37%
Inst Trans-3.86%
ROA-14.13%
ROE-16.90%
ROIC-16.83%
Gross Margin69.70%
Oper. Margin-78.98%
Profit Margin-81.40%
SMA20-21.18%
SMA50-12.15%
SMA2003.07%
Trades-

Technical

Shs Outstand103.23M
Shs Float94.82M
Short Float1.67%
Short Ratio1.55
Short Interest1.58M
52W High1.80 -39.06%
52W Low0.64 70.97%
Volatility13.77% 10.55%
ATR (14)0.13
RSI (14)37.06
Beta1.49
Rel Volume0.02
Avg Volume1.02M
Volume1,125

Performance

Perf Week-16.03%
Perf Month-12.00%
Perf Quarter-16.67%
Perf Half Y0.92%
Perf YTD-29.03%
Perf Year-30.38%
Perf 3Y-66.57%
Perf 5Y-91.25%
Perf 10Y-
Recom1.33
Target Price4.11
Prev Close1.10
Price1.10
Change %0.00%

Analyst ratings

latest 10 of 11
DateActionAnalystRating changeTargetImplied
Aug 11, 2025DowngradeBBTIG ResearchBuy → Neutral
Aug 07, 2025DowngradeWWilliam BlairOutperform → Mkt Perform
Jul 22, 2025InitiatedSStephensOverweight$6+445.5%
Nov 29, 2023InitiatedCCraig HallumBuy$7+536.4%
Oct 15, 2021ResumedCCowenOutperform
Aug 24, 2021InitiatedWWilliam BlairOutperform
Aug 24, 2021InitiatedWWedbushOutperform$36+3,172.7%
Aug 24, 2021InitiatedSStifelBuy$18+1,536.4%
Aug 24, 2021InitiatedSStephensOverweight$19+1,627.3%
Aug 24, 2021InitiatedCCowenOutperform

Peers

Mkt cap
TickerCompanyMkt cap
LABStandard BioTools Inc253.85M
TXG10x Genomics Inc7.81B
CTKBCytek BioSciences Inc746.78M
QSIQuantum-Si Incorporated260.39M
TKNOAlpha Teknova Inc540.96M
RGENRepligen Corp10.93B
DNAGinkgo Bioworks Holdings Inc659.93M
AZTAAzenta Inc2.06B
ABCLAbCellera Biologics Inc3.82B
AVTRAvantor Inc10.56B

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Swirsky Douglas JCHIEF FINANCIAL OFFICERMar 17 '26Sale0.8110,1428,266151,669Mar 19 04:05 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 696.31B
VXFVanguard Extended Market Index ETFAUM: 30.79B
VHTVanguard Health Care ETFAUM: 21.54B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 112.81M

News

latest 14 of 200
  • MaxCyte Beats Big And Raises Again, But The Akron Bio Deal Changes The Story (Earnings Whispers) -13.08%
  • MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance (GlobeNewswire)
  • MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base (GlobeNewswire)
  • MaxCyte's Raised Outlook Leaves Wall Street Lagging Ahead Of Third-Quarter Report (Earnings Whispers)
  • MaxCyte to Participate in Three Upcoming Investor Conferences (GlobeNewswire) +11.04%
  • MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance (GlobeNewswire) +29.63%
  • MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer (GlobeNewswire)
  • MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • MaxCyte launches CHANGE-seq-BE and ONE-seq-BE to strengthen off-target assessment for genome editing therapies (GlobeNewswire) +9.45%
  • MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ... (GuruFocus.com) +9.45%
  • MaxCyte Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • MaxCyte Announces Multi-Platform Technology License Partnership with Genentech to Advance Cell Therapy Development (GlobeNewswire) +5.13%
  • MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026 (GlobeNewswire)
  • MaxCyte Inc (MXCT) Q1 2026 Earnings Call Highlights: Revenue Meets Expectations Amid Core ... (GuruFocus.com) +24.06%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.050-0.078-0.05010.157.394
2026Q22026-08-12-0.080-0.090-0.0837.276.514
2026Q12026-05-12-0.040-0.076-0.0449.657.284
2025Q42026-03-24-0.090-0.076-0.0907.309.084
2025Q32025-11-12-0.120-0.112-0.1176.836.836
2025Q22025-08-06-0.120-0.102-0.1168.209.586
2025Q12025-05-07-0.100-0.097-0.09710.399.163
2024Q42025-03-11-0.100-0.120-0.1008.698.045
2024Q32024-11-06-0.110-0.120-0.1108.167.466
2024Q22024-08-06-0.090-0.123-0.09010.437.976
2024Q12024-05-07-0.090-0.125-0.09211.347.516
2023Q42024-03-12-0.050-0.068-0.05115.6713.446
2023Q32023-11-08-0.110-0.101-0.1098.008.876
2023Q22023-08-09-0.100-0.096-0.1029.0410.665
2023Q12023-05-10-0.110-0.112-0.1068.588.275
2022Q42023-03-15-0.050-0.078-0.04712.4212.405

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-0.170-0.180-0.17314.8316.70
2019FY-0.230-0.248-0.22921.6219.34
2020FY-0.170-0.195-0.17026.1726.20
2021FY-0.210-0.216-0.21133.8933.38
2022FY-0.230-0.256-0.23244.2644.24
2023FY-0.370-0.395-0.36741.2939.06
2024FY-0.390-0.411-0.39238.6338.15
2025FY-0.420-0.392-0.42033.0335.12
2026FY--0.256--34.08
2027FY--0.229--43.68
2028FY--0.194--57.48
2029FY--0.110--81.50

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-116227.597.208.10
2026Q4S2026-11-106217.627.208.10
2026Q4S2026-11-046007.517.108.10
2026Q4S2026-10-276017.517.108.10
2026Q4S2026-10-136067.517.108.10
2026Q4S2026-08-216057.527.108.10
2026Q4S2026-08-136047.787.108.74
2026Q4S2026-07-276017.937.188.74
2026Q4S2026-07-206157.937.188.74
2026Q4S2026-07-016248.007.188.74
2026Q4S2026-05-137257.937.188.74
2026Q4S2026-04-157058.757.809.90
2026Q4S2026-04-036058.567.809.88
2026Q4S2026-04-026058.567.809.88

Estimate history

EPS, annual-0.204-0.173-0.229-0.17-0.211-0.232-0.367-0.392-0.419-0.2634
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.11-0.1-0.097-0.116-0.117-0.09-0.044-0.083-0.046
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual13.98516.66721.62126.16933.89444.26241.28838.62733.02634.37
Period201720182019202020212022202320242025TTM
Sales, quarterly8.1648.69310.398.5076.8297.39.6517.27110.152
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual50.89651.33357.40477.382101.203102.398103.962105.711106.79103.233
Period201720182019202020212022202320242025MRQ
Shares, quarterly105.3105.711106.314106.592106.644106.79107.122106.134103.233
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue34.3733.0338.6341.2944.2633.8926.1721.6216.67
Cost of Goods Sold Incl. D&A10.4210.4511.248.737.635.002.772.501.84
Gross Profit23.9622.5827.3832.5636.6428.9023.4019.1214.83
Selling, General and Administrative Excl. Other51.1166.1278.4480.7863.9247.0134.3831.5223.24
Research and Development13.6920.8222.2323.8219.5115.4117.7417.6011.24
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-27.15-43.55-51.06-48.22-27.28-18.12-10.97-12.40-8.42
Interest Expense0.000.000.000.000.000.400.830.680.61
Unusual Expense6.688.280.000.000.000.650.00--
Net Income Before Taxes-27.98-44.63-41.05-37.92-23.57-19.08-11.82-12.89-8.87
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-27.98-44.63-41.05-37.92-23.57-19.08-11.82-12.89-8.87
Net Income From Continuing Operations-27.98-44.63-41.05-37.92-23.57-19.08-11.82-12.89-8.87
Net Income-27.98-44.63-41.05-37.92-23.57-19.08-11.82-12.89-8.87
EPS (Recurring)-0.23-0.36-0.39-0.37-0.23-0.21-0.17-0.23-0.17
EPS (Basic, Before Extraordinaries)-0.26-0.42-0.39-0.37-0.23-0.21-0.17-0.23-0.17
EPS (Diluted)-0.26-0.42-0.39-0.37-0.23-0.21-0.17-0.23-0.17
EBITDA-22.25-38.40-46.74-44.04-24.58-16.69-9.93-11.78-8.07
Non-Operating Income (Expense)5.857.2010.0010.293.710.08-0.020.180.16
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.979.2113.0813.9811.757.962.471.751.32
Price To Sales Ratio3.374.9911.2911.7612.5527.24---
Gross Margin69.7068.3670.8978.8682.7785.2689.4388.4488.96
Operating Margin-78.98-131.85-132.18-116.78-61.64-53.45-41.94-57.33-50.50
Net Margin-81.40-135.14-106.29-91.85-53.25-56.30-45.15-59.64-53.21
Shares Outstanding103.23106.79105.71103.96102.40101.2077.3857.4051.33
Market Capitalization113.53113.53438.81487.44557.181,023.42124.8393.5793.54

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue10.157.279.657.306.838.5110.398.69
Cost of Goods Sold Incl. D&A2.552.632.582.652.642.602.563.30
Gross Profit7.604.647.074.654.195.917.835.39
Selling, General and Administrative Excl. Other13.7112.7313.3411.3415.4320.1619.1918.21
Research and Development2.873.623.863.335.326.275.904.61
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.11-8.09-6.27-6.69-11.24-14.25-11.36-12.82
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.002.210.004.472.890.000.920.00
Net Income Before Taxes-4.76-8.87-4.75-9.60-12.42-12.36-10.26-10.60
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-4.76-8.87-4.75-9.60-12.42-12.36-10.26-10.60
Net Income From Continuing Operations-4.76-8.87-4.75-9.60-12.42-12.36-10.26-10.60
Net Income-4.76-8.87-4.75-9.60-12.42-12.36-10.26-10.60
EPS (Recurring)-0.05-0.07-0.04-0.06-0.10-0.12-0.09-0.10
EPS (Basic, Before Extraordinaries)-0.05-0.08-0.04-0.09-0.12-0.12-0.10-0.10
EPS (Diluted)-0.05-0.08-0.04-0.09-0.12-0.12-0.10-0.10
EBITDA-4.97-6.88-5.00-5.40-9.96-12.98-10.08-11.77
Non-Operating Income (Expense)1.341.431.521.561.721.902.022.23
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.961.161.140.711.543.513.043.13
Price To Sales Ratio3.374.232.335.014.896.497.6811.37
Gross Margin74.8663.8673.2263.6861.3469.4575.3862.03
Operating Margin-60.15-111.22-64.96-91.62-164.65-167.54-109.35-147.51
Net Margin-46.91-122.05-49.22-131.45-181.81-145.26-98.76-121.90
Shares Outstanding103.23106.13107.12106.79106.64106.59106.31105.71
Market Capitalization113.53131.7675.07165.34168.44231.78289.46438.81

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments103.04154.48168.29227.34255.0434.7616.7114.4425.34
Short Term Receivables3.504.685.7813.576.885.173.244.903.20
Inventories7.558.9112.238.585.204.323.702.241.35
Other Current Assets4.283.613.902.783.311.000.800.860.67
Total Current Assets118.37171.68190.19252.27270.4345.2524.4522.4530.55
Net Property, Plant & Equipment28.4530.4734.7533.5813.376.495.531.820.85
Total Investments and Advances52.5735.7842.940.000.000.000.000.000.00
Intangible Assets0.65-----0.000.000.00
Other Assets2.471.530.390.810.320.030.000.000.00
Total Assets202.51239.47268.27286.65284.1251.7829.9924.2731.40
Short Term Debt Incl. Current Port. of LT Debt1.460.860.770.160.530.670.510.000.85
Accounts Payable1.401.360.740.531.820.895.644.124.33
Other Current Liabilities11.4113.5516.3414.7413.2710.053.192.452.06
Total Current Liabilities14.2715.7817.8615.4315.6211.619.346.577.24
Long Term Debt16.4917.1717.9715.945.156.296.705.064.18
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.260.270.281.320.450.650.340.360.38
Total Liabilities31.0233.2236.1132.6921.2218.5516.3811.9911.80
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity171.49206.25232.17253.97262.9033.2313.6012.2819.60
Total Shareholders Equity171.49206.25232.17253.97262.9033.2313.6012.2819.60
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity171.49206.25232.17253.97262.9033.2313.6012.2819.60
Total Liabilities & Stockholders Equity202.51239.47268.27286.65284.1251.7829.9924.2731.40
Book Value Per Share1.611.952.232.482.600.430.240.240.39
Tangible Book Value Per Share1.601.952.232.482.600.430.240.240.39
Full-Time Employees9111414312584120104--
Price to Book Ratio0.752.052.092.193.923.356.885.82-
Return on Assets-20.20-16.17-13.67-8.26-11.36-28.90-47.54-31.87-41.78
Return on Equity-23.63-18.73-15.60-9.12-12.89-50.47-99.64-55.64-80.36
Return on Invested Capital-23.74-18.38-15.16-8.73-7.12-29.90-63.51-51.15-41.72
Quick Ratio7.7710.329.9715.8016.983.522.223.074.03
Current Ratio8.3010.8810.6516.3517.323.902.623.424.22

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-27.98-44.63-41.05-37.92-23.57-19.08-11.82-12.89-8.87
Depreciation4.895.144.324.172.701.421.050.610.34
Other Funds (Non Cash)7.3311.209.888.259.308.622.841.871.50
Funds from Operations-15.76-28.29-26.86-25.51-11.57-9.03-7.92-10.42-7.03
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-5.27-6.12-0.753.82-3.21-1.64-0.861.61-3.46
Cash from Operating Activities-21.02-34.41-27.61-21.69-14.78-10.68-8.78-8.80-10.49
Capital Expenditures-0.57-1.77-1.65-3.70-18.48-3.83-2.07-1.27-0.71
Net Assets From Acquisitions0.00-1.770.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.010.000.000.000.000.00
Purchase or Sale of Investments27.3329.488.5858.67-6.35-191.18-14.511.73-3.12
Purchase of Investments-83.37-126.29-150.86-255.09-290.94-268.68-22.51-7.42-12.67
Sale Or Maturity of Investments110.70155.76159.44313.77284.6077.508.009.159.55
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities26.7625.936.9354.98-24.82-195.01-16.580.45-3.83
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-5.330.662.062.142.89239.7128.9712.460.23
Repurchase of Common Pref Stock-5.500.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.170.662.062.142.89239.7128.9712.460.23
Proceedsfrom Stock Options0.120.220.460.270.00236.0828.5712.330.00
Issuance or Reduction of Debt, Net0.000.000.000.000.00-4.99-0.06-0.15-0.00
Change in Long Term Debt0.000.000.000.000.00-4.99-0.06-0.15-0.00
Issuance of Long Term Debt0.000.000.000.000.000.001.444.950.28
Reduction of Long Term Debt0.000.000.000.000.00-4.99-1.50-5.11-0.29
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities-5.330.662.062.142.89234.7228.9012.310.23
Net Change in Cash0.40-7.82-18.6235.44-36.7229.033.543.96-14.09
Free Cash Flow-21.45-36.18-29.26-25.39-33.26-14.51-10.85-10.07-11.20
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments101.28105.69106.85103.04105.73126.56
Short Term Receivables12.053.924.253.508.315.75
Inventories7.387.807.637.557.617.93
Other Current Assets3.963.864.214.283.002.97
Total Current Assets124.67121.27122.94118.37124.64143.22
Net Property, Plant & Equipment24.5825.3727.3428.4529.7530.75
Total Investments and Advances31.4736.2340.8152.5752.2738.60
Intangible Assets0.750.770.780.654.224.39
Other Assets1.011.032.612.472.582.80
Total Assets182.48184.67194.47202.51213.48219.75
Short Term Debt Incl. Current Port. of LT Debt1.561.531.371.461.311.31
Accounts Payable1.031.731.201.401.291.21
Other Current Liabilities13.326.637.6411.4113.509.04
Total Current Liabilities15.929.8910.2114.2716.1011.55
Long Term Debt15.3215.7216.1116.4916.8517.20
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.310.300.260.260.250.27
Total Liabilities31.5525.9226.5931.0233.2029.03
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity150.93158.75167.89171.49180.28190.72
Total Shareholders Equity150.93158.75167.89171.49180.28190.72
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity150.93158.75167.89171.49180.28190.72
Total Liabilities & Stockholders Equity182.48184.67194.47202.51213.48219.75
Book Value Per Share1.461.501.571.611.691.79
Tangible Book Value Per Share1.451.491.561.601.651.75
Full-Time Employees---91--
Price to Book Ratio0.750.780.440.920.881.16
Return on Assets-14.13-17.62-18.43-20.20-19.75-19.00
Return on Equity-16.90-20.39-21.30-23.63-23.19-21.73
Return on Invested Capital-2.86-5.09-2.58-5.10-6.30-5.94
Quick Ratio7.3711.4711.297.777.2711.71
Current Ratio7.8312.2612.048.307.7412.39

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-4.76-8.87-4.75-9.60-12.42-12.36
Depreciation1.141.211.271.291.281.48
Other Funds (Non Cash)0.571.680.924.161.782.81
Funds from Operations-3.05-5.99-2.57-4.15-9.35-8.07
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.451.33-5.601.461.89-1.79
Cash from Operating Activities-5.51-4.66-8.17-2.69-7.46-9.85
Capital Expenditures-0.06-0.06-0.22-0.23-0.30-0.58
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments7.926.632.889.915.492.12
Purchase of Investments-18.62-11.37-25.12-28.25-34.51-28.88
Sale Or Maturity of Investments26.5418.0028.0038.1640.0031.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities7.866.572.669.685.191.54
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-4.02-1.420.010.100.010.15
Repurchase of Common Pref Stock-4.02-1.480.000.000.000.00
Sale of Common Pref Stock0.000.060.010.100.010.15
Proceedsfrom Stock Options0.000.030.000.090.000.13
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-4.02-1.420.010.100.010.15
Net Change in Cash-1.670.48-5.517.09-2.25-8.16
Free Cash Flow-5.57-4.72-8.24-2.92-7.76-10.44

Revenue breakdown

Assay and Other Service2025: 1.97M
License2024: 16.41M 2025: 12.37M
Product2024: 21.09M 2025: 18.69M
Product and Service, Other2024: 1.13M
Non-US2024: 12.86M 2025: 11.95M
United States2024: 25.77M 2025: 21.08M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.67%1.6M94.8M888.67K
2026-10-151.93%1.8M94.8M827.37K
2026-09-301.15%1.1M94.8M725.66K
2026-09-151.24%1.2M94.8M1.05M
2026-08-311.37%1.3M94.8M1.10M
2026-08-141.29%1.2M95.1M1.21M
2026-07-311.26%1.2M98.8M1.24M
2026-07-151.42%1.4M98.8M1.22M
2026-06-301.53%1.5M98.8M1.17M
2026-06-154.28%4.2M99.1M943.81K
2026-05-294.51%4.5M99.1M1.01M
2026-05-154.77%4.7M99.1M1.01M
2026-04-305.30%5.2M98.9M1.09M
2026-04-155.48%5.4M98.8M1.17M
2026-03-315.62%5.6M98.8M1.13M
2026-03-135.56%5.5M98.7M1.07M
2026-02-275.83%5.8M98.7M1.20M
2026-02-135.16%5.1M98.7M1.21M
2026-01-303.93%3.9M98.7M1.03M
2026-01-152.54%2.5M98.7M913.72K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.000.08-1.000.00---
call5.000.000.000.00-0.000.00---
call7.500.000.000.00-0.000.00---
put2.500.000.001.17-7.000.00---
put5.000.000.000.00-0.000.00---
put7.500.000.000.00-0.000.00---

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-09SEC
2026-11-02SCHEDULE 13DSEC
2026-10-15SCHEDULE 13DSEC
2026-10-148-KCurrent report2026-10-14SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-08-04SCHEDULE 13DSEC
2026-07-29SCHEDULE 13G/ASEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-178-KCurrent report2026-06-17SEC
2026-06-168-KCurrent report2026-06-10SEC
2026-05-14SCHEDULE 13DSEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-128-KCurrent report2026-05-12SEC
2026-04-29ARSAnnual report to security holders. 2025-12-31SEC
2026-04-29DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-17SEC
2026-04-174Statement of changes in beneficial ownership of securities2026-04-15SEC
2026-04-15S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-04-10SCHEDULE 13G/ASEC
2026-04-104Statement of changes in beneficial ownership of securities2026-03-30SEC
2026-04-103Initial statement of beneficial ownership of securities2026-03-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-03008.27K1
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Capricorn Fund Managers Ltd7.95%
Vitruvian Partners LLP4.71%
VANGUARD CAPITAL MANAGEMENT LLC3.76%
MORGAN STANLEY3.45%
Mudita Advisors LLP3.15%
BlackRock, Inc.2.86%
BNP Paribas Asset Management Holding S.A.2.59%
CADIAN CAPITAL MANAGEMENT, LP2.05%
Peapod Lane Capital LLC1.92%
RENAISSANCE TECHNOLOGIES LLC1.78%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.56%
VANGUARD EXTENDED MARKET INDEX FUND1.08%
Fidelity Small Cap Index Fund0.92%
Fidelity Extended Market Index Fund0.53%
VANGUARD RUSSELL 2000 INDEX FUND0.48%
Inception Portfolio0.32%
VANGUARD HEALTH CARE INDEX FUND0.28%
EQ/Morgan Stanley Small Cap Growth Portfolio0.20%
Schwab Small-Cap Index Fund0.20%
Fidelity Total Market Index Fund0.19%

OakChart. MXCT. Cached 15 minutes.